Navigation Links
Favrille Announces Results From Study Showing Enhanced Activity,From Insect Cell-Derived Immunotherapy for Lymphoma

Data Reported at American Association for Cancer Research Annual Meeting

SAN DIEGO, April 18, 2007 /PRNewswire-FirstCall/ -- Favrille, Inc. , a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced results from a new study showing enhanced activity from insect-cell derived idiotype (Id) proteins, a key component in the Company's Id/KLH immunotherapy product candidate FavId(R) for B-cell non-Hodgkin's lymphoma (NHL), compared to Id proteins produced using mammalian cells. The data were reported today at the American Association for Cancer Research (AACR) Annual Meeting in Los Angeles.

"Our data show that production of recombinant Id proteins via an insect cell system results in a structurally different antigen with improved immunogenicity compared to mammalian cell-derived Id proteins," said co-author John Timmerman, M.D., and Assistant Professor of Medicine, Division of Hematology and Oncology at the University of California, Los Angeles, where much of the study was performed. "This in turn may lead to improved activity of the final Id-KLH immunotherapy for lymphoma."

A copy of the poster presented by Dr. Timmerman, entitled "Enhanced Immunostimulation by a Therapeutic Lymphoma Idiotype Vaccine Produced in Insect Cells Involves Mannose Receptor Targeting to Antigen Presenting Cells," is now available on the Investor Relations section of Favrille's web site at www.favrille.com.

"This study demonstrates that Id protein produced by insect cell lines possesses an enhanced ability to interact with dendritic cells compared to the same protein produced in mammalian cells, which in turn stimulates an enhanced immune response," said Daniel Gold, Ph.D., Favrille's Chief Scientific Officer. "These data help support our belief that the use of insect cells provides not only the most eff
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkins Lymphoma in Europe
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:8/29/2014)... , August 29, 2014 ... Seed Oil Market by Extraction type (SFE, Cold ... & Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) ... by MarketsandMarkets, defines and segments the Amaranth Seed ... the market size in terms of value. The ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely ... a generation ago are returning. Measles was declared eliminated ... in 2014 as of August 15—the highest incidence in ... public health department declared whooping cough a problem of ... are getting sick and dying from these preventable diseases—in ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3
... survival in,postmenopausal women with early breast cancer ... demonstrated for an AI over tamoxifen,in a ... 15 June 2007: Analysis of the entire,population ... survival in,early breast cancer can be significantly ...
... 18, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced that ... following interim analysis of data,from the first 41 ... an,angiogenesis product candidate using Vical's DNA delivery,technology. Based ... the trial had been achieved with statistical,significance and ...
Cached Medicine Technology:First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex 2First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex 3First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex 4First single breast cancer study to show significant survival,benefit for women switching from tamoxifen to Arimidex 5Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 2Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 3Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 4Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan 5
(Date:9/1/2014)... 01, 2014 The National Association of ... that Dawn Bazarko, DNP, MPH, RN, and Adriana Perez, ... American Academy of Nursing. They will be inducted with ... FACHE, whose induction we reported last May. , Our ... during the 2014 American Academy of Nursing Policy Conference ...
(Date:9/1/2014)... Registration is now open for the 4th Annual ... to be held on Sunday, September 21, 2014. The event ... Meadow in Secaucus, New Jersey. All proceeds from the race ... to restoring a sense of self, restoring the family unit, ... families. , General registration is $30 with special pricing for ...
(Date:9/1/2014)... San Diego, CA (PRWEB) September 01, 2014 ... website daily regarding all the latest information from the ... , The US FDA announced on August 28, ... are recalled (Class I) as the device ... FDA, the DePuy Synthes Craniomaxillofacial (CMF) Distraction System is ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 ... into Heartbeat Experts’ perspectives on stakeholder ... , Download the flash report to speak ... any launching Diabetes product:, , ... an increasingly crowded market ,     Understanding ...
(Date:8/31/2014)... 31, 2014 Just in time for Washington’s ... only wild, sustainable Alaska Salmon, award winning chowder ... Duke's Green Lake location , Sunday, September 28, 2014 ... sample several ethnic salmon BBQ culinary delights. Live music will ... from Hawaii, Puerto Rico and Mexico will be featured. ...
Breaking Medicine News(10 mins):Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Hope For The Warriors New Jersey Run to Honor Wounded and Families of the Fallen 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Diabetes Products 2Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2
... ... and Insurance Services, a leading provider of information-based technology services to the ... in Louisiana and Texas in addition to its services that are provided ... headquartered in Hampton, New Hampshire and is owned by Medical Protective, part ...
... , , ARLINGTON, Va., ... that a panel of independent scientific experts convened by the ... a reproductive or developmental toxicant. After a thorough review ... Committee determined that bisphenol A should not be listed under ...
... WASHINGTON, July 15 On behalf of the nation,s mayors, ... commended President Barack Obama, the House of Representatives and the Senate ... transformative health care reform legislation. , ... times because they are not able to afford health insurance and, ...
... , SCOTTSDALE, Ariz., July 15 Grubb ... of America, Inc.) (the "REIT"), a self-managed non-traded real estate ... agreement (the "Agreement") to acquire a 16 building portfolio from ... transaction involves approximately 855,000 square feet of medical office and ...
... , , CARY, N.C., ... CRTX ), a specialty pharmaceutical company focused on acquiring, ... and related markets, today announced that it has submitted ... Administration (FDA) for an extended-release antitussive product (CRTX 067) ...
... , , , ... presented today, the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory ... and docetaxel did not provide a sufficient benefit-risk ... cancer. , , Women with locally advanced ...
Cached Medicine News:Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 2Health News:Garnet Health -- A Leader in the Healthcare Industry Expands its Operations 3Health News:California Expert Panel Concludes Bisphenol A is Not a Reproductive or Developmental Toxicant 2Health News:The Nation's Mayors Commend New Healthcare Reform Legislation 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: